Chinese electric vehicle maker GAC Nio has filed a new patent for a "health adjustment system" that collects physiological data from the vehicle's driver, according to data provider Qichacha.

The system is used in vehicles and includes a physiological data collection device and a central controller.

Based on physiological data from the collection device, the central controller monitors the health status of the driver.

When the system detects the driver's abnormal health status, it will regulate the health status of the driver through human-machine interaction.

The system is capable of timely and accurate health adjustments to ensure safe driving on the road.

GAC Nio is an independent company jointly invested by GAC and Nio. Neither GAC nor Nio's parent company assigns management personnel to this company or participates in the business management.

GAC Nio does not manufacture any product of GAC or Nio. Simply put, Nio is simply an investor and there is no other relationship between the parties, Nio says.

In 2019, GAC Nio released its first product, HYCAN 007. When deliveries began, GAC Nio revised its projected deliveries downward from reaching 15,000 units in 2020 to 5,000 to 10,000 units.

In the first 11 months of 2020, HYCAN 007 accumulated sales of only 631 units, including only 3 units in November 2020.

GAC NIO CEO reportedly to leave company in March

(Source: GAC Nio website)